181 related articles for article (PubMed ID: 31328457)
1. Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
Chung YW; Kim S; Hong JH; Lee JK; Lee NW; Lee YS; Song JY
J Gynecol Oncol; 2019 Sep; 30(5):e75. PubMed ID: 31328457
[TBL] [Abstract][Full Text] [Related]
2. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
3. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
Cao GD; Chen K; Chen B; Xiong MM
BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126
[TBL] [Abstract][Full Text] [Related]
4. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
8. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
9. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.
Seo AN; Kwak Y; Kim WH; Kim DW; Kang SB; Choe G; Lee HS
Virchows Arch; 2015 Jun; 466(6):645-54. PubMed ID: 25739551
[TBL] [Abstract][Full Text] [Related]
10. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
11. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW
Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460
[TBL] [Abstract][Full Text] [Related]
12. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
13. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
17. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
20. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
